Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lyophilized allogeneic fecal microbiota
- Development stage
- Unknown
- Lead developer
- Vrije University Medical Center
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lyophilized allogeneic fecal microbiota is an investigational microbiome-based therapeutic developed by Amsterdam UMC. It consists of pooled donor fecal microbiota that has been freeze-dried (lyophilized) and encapsulated for oral administration. The product aims to modulate the gut microbiome, restore microbial diversity, and reduce systemic inflammation. It is currently being evaluated in the CACHEXIS clinical trial as an adjunctive therapy to standard chemotherapy (paclitaxel and ramucirumab) for patients with advanced gastroesophageal cancer and cancer cachexia, with the goal of improving nutritional status and treatment response.
- Other names
- lyophilized pooled allogeneic fecal microbiotaFMT capsulesfecal microbiota transplantation capsules
Beyond the preview
Go deeper on lyophilized allogeneic fecal microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lyophilized allogeneic fecal microbiota.